Single-blind, Partially Randomised, Placebo-controlled Phase I Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 655130 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs BI 655130 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2016 Number of arms changed from one to two and study design changed to single group assignment to parallel and randomized as reported by ClinicalTrials.gov record.